# Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease

> **NCT02837237** · PHASE1 · COMPLETED · sponsor: **KBP Biosciences** · enrollment: 11 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** KBP-5074

## Key facts

- **NCT ID:** NCT02837237
- **Lead sponsor:** KBP Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-13
- **Primary completion:** 2016-12-20
- **Final completion:** 2017-06-30
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02837237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02837237, "Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02837237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*